Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Hezar Jarib Ave., Isfahan, Iran.
Bioinformatics Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Med Oncol. 2024 Oct 14;41(11):264. doi: 10.1007/s12032-024-02511-5.
DNA Fragmentation Factor (DFF) is a heterodimer protein involved in DNA fragmentation during apoptosis, which acts as a trigger downstream of caspase-3 activation. DFF40 catalytically active homo-oligomers break down chromosomal DNA. Previous scientific investigations have revealed a link between DFF40 expression changes and various cancers. DFF40 deletion or down-regulation has been observed in some cancers. Consequently, therapeutic strategies involving the DFF40 molecule compensating led to an increased rate of cancer cell apoptosis. In this review article, we aimed to introduce cancers with low expression of this protein first. The second part of this paper focuses on studies that utilized exogenous DFF40 protein produced by recombinant DNA technology and surveyed during in vitro and in vivo tests. Finally, compensation for diminished expression of the mentioned protein via gene therapy-based techniques to make up for this apoptotic molecule's low expression is the topic of the last part of this review article.
DNA 断裂因子（DFF）是一种参与细胞凋亡过程中 DNA 片段化的异源二聚体蛋白，作为 caspase-3 激活下游的触发因子。DFF40 催化活性同型寡聚体分解染色体 DNA。先前的科学研究表明，DFF40 表达变化与各种癌症之间存在关联。在一些癌症中观察到 DFF40 的缺失或下调。因此，涉及 DFF40 分子补偿的治疗策略导致癌细胞凋亡率增加。在这篇综述文章中，我们首先旨在介绍这种蛋白低表达的癌症。本文的第二部分重点介绍了利用重组 DNA 技术产生的外源性 DFF40 蛋白并在体外和体内试验中进行调查的研究。最后，通过基于基因治疗的技术来补偿所述蛋白表达的降低，以弥补这种凋亡分子的低表达，是本文最后一部分的主题。
